Literature DB >> 21904398

[Biochemical diagnosis of monomeric hyperprolactinemia].

A Rivero Marcotegui1, A García-Calvo.   

Abstract

BACKGROUND: Prolactin can take several molecular forms of which the most biologically active is the monomeric form (PRLm). The presence of macroprolactin (MPRL) can give rise to a false diagnosis of hyperprolactinemia due to interference in the measuring procedure. The aim was to develop a protocol that enables diagnosis of monomeric hyperprolactinemia, which should also be complementary to the procedure for detecting MPRL.
MATERIAL AND METHODS: The reference population for PRLm was made up of 122 healthy women and 140 healthy men, from whom blood was extracted for PRL quantification. Additionally, 49 hyperprolactinemic serums (33 women and 16 men) were collected. PRL was quantified in all the samples in an Immulite 2000. The detection of MPRL and PRLm was carried out following precipitation with polyetylenglicol (PEG). The result was confirmed by gelatin filtration chromatography. The reference values were obtained following the indications of the Expert Panel of the IFCC.
RESULTS: The PRLm reference values were 3,4 - 26,6 µg/L and 4,6 - 16,4 µg/L in women and men, respectively. In 57% of the 49 hyperprolactinemic patients the concentration of PRLm following PEG fell outside the previously obtained reference interval, confirming the presence of monomeric hyperprolactinemia.
CONCLUSIONS: A protocol for quantifying PRLm has been developed and implemented. Obtaining PRLm reference values makes it possible to diagnose monomeric or active hyperprolactinemia in a complementary form to the identification of MPRL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21904398     DOI: 10.4321/s1137-66272011000200002

Source DB:  PubMed          Journal:  An Sist Sanit Navar        ISSN: 1137-6627            Impact factor:   0.829


  1 in total

Review 1.  Prolactin and Autoimmunity.

Authors:  Vânia Vieira Borba; Gisele Zandman-Goddard; Yehuda Shoenfeld
Journal:  Front Immunol       Date:  2018-02-12       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.